Loading stock data…
AVTX
$13.71+0.31 (+2.31%)
Market ClosedLast close May 1
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Avalo Therapeutics, Inc. in the Healthcare sector is trading at $13.71. The stock is currently 34% below its 52-week high of $20.72, remaining 3.7% below its 200-day moving average. Technical signals show neutral RSI of 53 and bearish MACD signal, explaining why AVTX maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 53) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$13.71
Potential Upside
5%
Whystock Fair Value$14.40
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$40.09+192.4%
Range$24.00 – $52.00
Fundamentals
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$330.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.94
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-94.23%
Volume
Today's trading volume
720,704
Recent News
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
Small drug stocks like Indivior gain traction as biotech recovery strengthens, fueled by innovation, M&A activity, and promising pipeline developments.
Avalo Therapeutics (NASDAQ:AVTX) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Here Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More
Pre-Market Stock Futures: Futures are trading mixed as we get ready to kick off the first-quarter earnings season next week, and, as usual, the big money-center banks and brokerage firms will headline the first results. All of the major U.S. indices saw wild swings on Thursday, and after opening the day deep in the red, ... Here Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 113.3% in Avalo Therapeutics (AVTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.